Yaz

/ Bayer

The tablets must be taken every day at about the same time, if necessary with a little liquid, in the order shown on the blister pack. Tablet taking is continuous. One tablet is to be taken daily for 28 consecutive days. Each subsequent pack is started the day after the last tablet of the previous pack. Withdrawal bleeding usually starts on day 2-3 after starting the placebo tablets (last row) and may not have finished before the next pack is started.
See prescribing information for full details.

Oral contraception.Treatment of moderate acne vulgaris in women who seek oral contraception.Treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who have chosen oral contraceptives as their method of birth control. The efficacy of YAZ for PMDD was not assessed beyond 3 cycles. YAZ has not been evaluated for treatment of PMS (premenstrual syndrome).

Venous thrombosis present or in history (deep venous thrombosis, pulmonary embolism). Arterial thrombosis present or in history (e.g. MI) or prodromal conditions (e.g. angina pectoris and transient ischemic attack). Cerebrovascular accident present or in history. The presence of a severe or multiple risk factor(s) for arterial thrombosis: diabetes mellitus with vascular symptoms; severe hypertension; severe dyslipoproteinemia. Hereditary or acquired predisposition for venous or arterial thrombosis, such as APC-resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant). Pancreatitis or a history thereof if associated with severe hypertriglyceridemia. Presence or history of severe hepatic disease as long as liver function values have not returned to normal. Severe renal insufficiency or acute renal failure. Presence or history of liver tumours (benign or malignant). Known or suspected sex-steroid influenced malignancies (e.g. of the genital organs or the breasts). Undiagnosed vaginal bleeding. History of migraine with focal neurological symptoms. Known or suspected pregnancy. Hypersensitivity to the active substances or to any of the excipients.

As with all COC’s.The progestin component is an aldosterone antagonist with potassium sparing properties. In most cases, no increase of potassium levels is to be expected. In a clinical study, however in some patients with mild or moderate renal impairment and concomitant use of potassium-sparing medicdbinal products, serum potassium levels slightly, but not significantly, increased during drospirenone intake. Therefore, it is recommended to check serum potassium during the first treatment cycle in patients presenting with renal insufficiency and a pretreatment serum potassium in the upper reference range, and particularly during concomitant use of potassium sparing medicdbinal products. Each light pink tablet of this medicdbinal product contains 46 mg lactose per tablet, each white tablet contains 50 mg. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption who are on a lactose-free diet, should take this amount into consideration.
Prior to the initiation or reinstitution, a complete medicdbal history (including family history) should be taken and pregnancy must be ruled out. Blood pressure should be measured and a physical examination should be performed. See prescribing information for full details.

Headache, nausea, mood changes, breast pain, irregular menstrual cycle.
See prescribing information for full details.

See prescribing information for full details.